# A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

> **NCT04201457** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pediatric Brain Tumor Consortium** · enrollment: 57 (actual)

## Conditions studied

- Low Grade Glioma (LGG) of Brain With BRAF Aberration
- High Grade Glioma (HGG) of the Brain With BRAF Aberration
- Low Grade Glioma of Brain With Neurofibromatosis Type 1

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT04201457
- **Lead sponsor:** Pediatric Brain Tumor Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-17
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04201457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04201457, "A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04201457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*